Search

Your search keyword '"Barozzi, Chiara"' showing total 3 results
Start Over Author "Barozzi, Chiara" Topic pharmacodynamics
3 results on '"Barozzi, Chiara"'

1. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome

Author

Toso, Anna, De Servi, Stefano, Leoncini, Mario, Angiolillo, Dominick J., Calabrò, Paolo, Piscione, Federico, Cattaneo, Marco, Maffeo, Diego, Bartorelli, Antonio, Palmieri, Cataldo, De Carlo, Marco, Capodanno, Davide, Genereux, Philippe, Bellandi, Francesco, Barozzi, Chiara, Tomasi, Luciana, Della Riva, Diego, and Palmerini, Tullio

Published
2017
Full Text
View/download PDF

2. A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study

Author

Palmerini, Tullio, Barozzi, Chiara, Tomasi, Luciana, Sangiorgi, Diego, Marzocchi, Antonio, De Servi, Stefano, Ortolani, Paolo, Bacchi Reggiani, Letizia, Alessi, Laura, Lauria, Giulia, Bassi, Mirna, and Branzi, Angelo

Subjects
*CLOPIDOGREL, *PLATELET aggregation inhibitors, *INFLAMMATORY mediators, *MYOCARDIAL infarction complications, *PHOSPHOPROTEINS, *C-reactive protein, *PHARMACODYNAMICS, *RANDOMIZED controlled trials
Abstract

Abstract: Introduction: The antiplatelet effect of standard or increased clopidogrel doses in patients with ST- segment elevation acute myocardial infarction (STEMI) has never been studied. In this study we compared the antiplatelet effect of a 75mg daily maintenance dose of clopidogrel with 150mg in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Materials and methods: Fifty-four patients with STEMI undergoing PCI were randomly allocated to receive either 75mg/day clopidogrel (group 1) or 150mg/day (group 2) for 1month. Platelet function, measured by 5 different assays, was determined at 3 time points: 38±8 hours after the procedure, 1week and 1month after randomization. Results: In group 1, mean ± SD platelet reactivity index (PRI) measured with the VASP assay was 57.7±15.7% and 46.9±15.7% at 1week and 1month, respectively, compared to 38.8±15.7% and 34.9±12.6% in group 2 (p=0.0001). Same results were observed for light transmittance aggregometry, whole blood aggregometry and VerifyNow, but not for thromboelastometry. In contrast to what may be expected, the 75mg daily maintenance dose took longer than 1-week to provide the full clopidogrel antiplatelet effect. Furthermore, patients in group 2 had a nearly 50% reduction in C-reactive protein levels both at 1week and 1month. Conclusion: In patients with STEMI and poor responsiveness to clopidogrel a 150mg daily maintenance dose of clopidogrel is associated with a significant reduction of platelet aggregation and a trend towards reduced inflammation. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

3. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome

Author

Francesco Bellandi, Marco Cattaneo, Mario Leoncini, Marco De Carlo, Cataldo Palmieri, Diego Maffeo, Luciana Tomasi, Diego Della Riva, Tullio Palmerini, Davide Capodanno, Paolo Calabrò, Philippe Généreux, Anna Toso, Antonio L. Bartorelli, Dominick J. Angiolillo, Federico Piscione, Chiara Barozzi, Stefano De Servi, Toso, Anna, De Servi, Stefano, Leoncini, Mario, Angiolillo, Dominick J., Calabro', Paolo, Piscione, Federico, Cattaneo, Marco, Maffeo, Diego, Bartorelli, Antonio, Palmieri, Cataldo, De Carlo, Marco, Capodanno, Davide, Genereux, Philippe, Bellandi, Francesco, Barozzi, Chiara, Tomasi, Luciana, Della Riva, Diego, and Palmerini, Tullio

Subjects
medicine.medical_specialty, Acute coronary syndrome, Ticlopidine, Statin, medicine.drug_class, medicine.medical_treatment, High platelet reactivity, 030204 cardiovascular system & hematology, Coronary artery disease, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, P2Y12, Internal medicine, medicine, Humans, cardiovascular diseases, 030212 general & internal medicine, Clopidogrel, Pharmacodynamics, Statins, Aged, Aged, 80 and over, Pharmacodynamic, business.industry, Percutaneous coronary intervention, Hematology, Odds ratio, Middle Aged, Platelet Activation, medicine.disease, Cardiology and Cardiovascular Medicine, Conventional PCI, Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, medicine.drug
Abstract

Statin use is associated with enhanced pharmacodynamic response to clopidogrel in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). However, the impact of statin therapy on clopidogrel response profiles in patients with acute coronary syndrome (ACS) undergoing PCI has not been established and represents the objective of this investigation. On-treatment -P2Y(12) platelet reactivity was measured using the vasodilator stimulated phosphoprotein (VASP) phosphorylation assay before PCI, at hospital discharge, and at 1 month after PCI in ACS patients enrolled in the multicenter, prospective GEne polymorphisms, Platelet Reactivity, and Syntax Score (GEPRESS) study (n = 962). High platelet reactivity (HPR) was defined as platelet reactivity index >= 50%. Statins were prescribed at hospital discharge in 87% (n = 835) of patients. All patients were followed for 1 year. The 1-month HPR rate was lower in statin than in non-statin treated patients (39.6 vs 52%, respectively, p=0.009). This finding was confirmed also among statin-treated patients with high Syntax score (>= 15). After adjustment for differences in baseline characteristics, statin use at discharge was independently associated with 1-month HPR rate (odds ratio, 0.58, 95% confidence interval, 0.38-0.89; p=0.015). In ACS patients undergoing PCI treated with clopidogrel the use of statins at discharge was associated with significantly lower 1-month HPR rates compared with patients not treated with statins.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results